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Abstract A 44-year-old male developed interstitial lung
disease (ILD) during treatment with rituximab (375 mg/m2
weekly intravenous 9 4 weeks) for the management of
immune thrombocytopenia (ITP). After 1 month of treat-
ment he developed dyspnea, fever (38.9 C), an increase of
C-reactive protein (CRP) and white blood cells with
hypoxemia, and decreased platelets. Chest X-ray and high-
resolution computed tomography revealed diffuse bilateral
lung infiltrates. He was diagnosed with severe ILD; ritux-
imab was discontinued, and treatment with fluticasone
combined with salmeterol, methylprednisolone, and
omeprazole was started, with an improvement of symptoms
over 15 days with normalization in CRP at 30 days.
A Naranjo assessment score of 6 was obtained, indicating a
probable relationship between the patient’s symptoms and
the suspect drug. In conclusion, in ITP patients treated with
rituximab, we suggest evaluating pulmonary endpoints
through pharmaco-epidemiological observational studies.
Introduction
Immune thrombocytopenia (ITP) is an autoimmune disor-
der characterized by platelet destruction, impaired throm-
bopoiesis and increased risk of bleeding [1]. The incidence
of ITP is not exactly defined, but is estimated at 3.3 per
100,000 persons annually [2].
Management of ITP involves corticosteroids (i.e., dex-
amethasone or prednisone) ± intravenous immunoglobulin
as initial treatment (recommendation: A). Splenectomy
(recommendation: 1B) may be offered to those with
chronic and severe (i.e., serious bleeding), or relapsing ITP
[3, 4]. In patients failing standard treatments (or with a
contra-indication to splenectomy), treatment with off-label
rituximab (recommendation: 2C) or thrombopoietin
receptor agonists (recommendation: 2C) is available.
Rituximab is a chimeric murine/human immunoglobulin
G1 (IgG1) kappa monoclonal anti-CD20 antibody
approved for use in lymphoma and rheumatoid arthritis [5,
6]. Considering its mechanism of action [i.e., destruction of
CD20(?) B cells and normalization of abnormal auto-re-
active T cells responsible for IgG autoantibody], rituximab
is also used ‘off-label’ in other autoimmune diseases [7–9].
Rituximab treatment is frequently efficacious and generally
well tolerated. However, some cases of rituximab-associ-
ated interstitial lung disease (ILD) have been reported [10–
12] and, to date, the incidence of rituximab-induced ILD is
estimated at 0.01–0.03 % [13, 14]. We report an additional
patient with ITP that developed ILD during treatment with
rituximab.
Case Description
A 44-year-old man with an 8-year history of ITP presented
with a history of 7 days of diarrhea, fever, vomiting, and
asthenia. Initial evaluation revealed the presence of dysp-
nea, temperature of 38.9 C, and emesis (six episodes/day),
but was normotensive (125/82 mmHg). The patient had
been treated for ITP for 5 years with prednisone
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(50 mg/daily, orally). Approximately 1 month before pre-
sentation he began treatment with rituximab (375 mg/m2
weekly intravenous 9 4 weeks). Review of systems
revealed no other significant factors. Pulse oximetry and
analysis of arterial blood gasses revealed hypoxemia (PO2
77 %). The patient had mild elevations of C-reactive pro-
tein (CRP; 12 mg/dL; normal range 0.5–10 mg/L), ery-
throcyte sedimentation rate (ESR) of 7 mm/h (normal range
\5 mm/h), white blood cells (14,850 per lL; normal range
4500–11,000 per lL), and markedly decreased platelets
(14,000/mL; normal range 150,000–400,000/mL). Chest
X-ray and high-resolution computed tomography revealed
diffuse bilateral lung infiltrates, while pulmonary-function
tests demonstrated a restrictive pattern and a diffusion
deficit that was consistent with interstitial disease. Bron-
choscopy revealed no endobronchial disease, and a bron-
cho-alveolar lavage fluid analysis excluded the presence of
bacterial, viral, and fungal infections. Cyto-immunological
analysis revealed increased cellularity (253 9 106/L) with
a decreased percentage of macrophages (62 %) and an
increased percentage of eosinophils (18 %).
A diagnosis of ILD probably related to rituximab was
postulated (Naranjo probability scale [15] score of 6).
Rituximab and prednisone were discontinued. Treatment
with fluticasone ? salmeterol (inhaler), methylpred-
nisolone (1 g/day for 3 days and 500 mg/day for 2 days),
and omeprazole (40 mg/day) was started with improve-
ment of symptoms at 15 days and normalization of CRP
(6.3 mg/L) and ESR (2.4 mm/h) at 30 days. Chest X-ray at
4 months revealed only minimal peripheral irregularities in
apices. At 7 months, the patient had complete remission of
both radiologic signs and clinical symptoms. The patient
provided written informed consent for the publication of
this case report.
Discussion
We report the development of ILD during off-label treat-
ment with rituximab for ITP. Many drugs may induce ILD
(i.e., chemotherapy agents like bleomycin, cyclophos-
phamide, and chlorambucil; cardiovascular drugs such as
amiodarone, b-blockers, and statins; anti-inflammatory
drugs including sulfasalazine, gold salts, and methotrexate;
antimicrobial agents including nitrofurantoin, ampho-
tericin, and minocycline; biological agents such as etan-
ercept, infliximab, and adalimumab; and
immunosuppressants including everolimus and sirolimus
[16–18]). This patient received none of these agents.
Fontana et al. [19] previously identified three ILD patients
associated with severe ITP, postulating that platelet
destruction may induce the development of pulmonary
inflammation. We observed a delayed temporal association
between rituximab treatment and the development of ILD.
Respiratory symptoms appeared following rituximab
administration (third cycle) and resolved upon its
discontinuation.
In agreement with our previous papers [20–23], using
the Naranjo probability scale, a Naranjo assessment score
of 6 was calculated, indicating a probable relationship
between symptom development and use of rituximab. For
ethical reasons we did not perform rituximab re-challenge.
Two recent reviews documented the development of
ILD during rituximab treatments associated with
chemotherapeutic agents [10, 24]; however, the exact role
of rituximab in ILD development has not been well
defined.
Paradoxically, it has been postulated that rituximab may
be used in the treatment of systemic sclerosis and systemic
lupus erythematosus-related lung disease [25, 26]. These
diseases are B-cell mediated; therefore, rituximab reduc-
tion of B-cell activation may reduce cytokine secretion
(i.e., IL-1) and resultant tissue damage.
However, in five patients with autoimmune disease,
treated with rituximab, Lavie et al. [27] reported a signif-
icant increase in serum protein level of cytokine B-cell
activating factor [tumor necrosis factor (TNF) family,
BAFF] 12 weeks after treatment, probably related to a
decrease in BAFF receptors and a resultant release of
BAFF, or to a delayed regulation of BAFF mRNA tran-
scription. These effects may induce an activation of B cells
with increased production of TNF.
Additionally, Bienvenu et al. [28], in a clinical trial of
400 elderly patients with previously untreated diffuse large
B-cell lymphoma randomized to cyclophosphamide, dox-
orubicin, vincristine, and prednisone (CHOP) or to ritux-
imab ? CHOP, reported that rituximab increases the
therapeutic efficacy of the CHOP regimen without the
development of serious adverse drug reactions. However,
in the rituximab-treated group, the authors found higher
mean plasma levels of TNFa (250 % 1 h after rituximab
administration and 180 % 8 h after rituximab administra-
tion). We previously reported that cell cultures stimulated
by TNFa had activation of p38 MAPK signalling pathway,
and this activation may be involved in cytokine release (IL-
6, IL-8, and IL-11) with epithelial apoptosis and fibroblast
proliferation [29–31] mediating ILD. A similar mechanism
has been postulated by other authors who described the
development of ILD during treatment with TNFa inhibitors
[32–35].
The exact role of TNFa in rituximab induced-ILD is yet
to be clarified. An additional possible mechanism of
rituximab toxicity may be related to increased activity of
immune cells (i.e., lymphocytes) that stimulate the prote-
olytic activation of IL-1b and IL-18, usually regulated by
innate immune receptors which are able to form large
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multiprotein signalling platforms, termed inflammasomes
[36]. Recently, Kong et al. [12] reported the development
of ILD in a 30-year-old man after four cycles of rituximab
treatment manifesting an increase in the expression of
inflammasome components nod-like receptor pyrin
domain-containing protein 3 (NLRP3).
To date, there is a paucity of data associating rituximab
with ILD in patients with ITP [11, 12, 37]. Protopapadakis
et al. [37] described the development of ILD in a 72-year-
old man with ITP receiving four cycles of rituximab in 1
month. This subject was treated with three rounds of 1 g IV
methylprednisolone, weaning to 15 mg of oral pred-
nisolone for 3 months, resulting in clinical improvement.
Child et al. [11] reported an 88-year-old poly-treated male
with ITP that developed ILD during treatment with ritux-
imab. In both reports the authors noted that advanced age
may have played a role in treatment with other drugs, and
in which corticosteroid treatment induced a clinical
improvement.
In agreement with these prior reports, we identified the
development of ILD approximately 1 month after initiating
rituximab; unlike prior reports, our 44-year-old male sub-
ject had no other systemic diseases except ITP, for which
he had been treated long term with prednisone (5 years).
To date, this appears to be only the second report, fol-
lowing Kong, associating the development of ILD in a non-
elderly adult treated with rituximab for ITP.
Case reports, by definition, have a limited scope of
presentation. Pharmaco-epidemiological observational
studies of pulmonary endpoints in ITP patients treated with
rituximab will be required to validate our observations. We
recognize the additional limitation of the lack of an
anatomical diagnosis using open-lung biopsy precluded by
risk of bleeding in our thrombocytopenic patient. Since
ILD was a delayed presentation in our subject, we did not
perform therapeutic drug monitoring of rituximab and
cannot exclude drug overdose. However, standard ritux-
imab dosing regimens were employed and our patient did
not take any other medication known to induce a drug–drug
interaction. In conclusion, ILD may present weeks to
months after rituximab exposure and can mimic many
pulmonary syndromes. We therefore recommend careful
respiratory monitoring in patients receiving repeated
rituximab administrations.
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